Skip to main content

A randomized, sham controlled clinical trial to assess the effectiveness of a positive end expiratory device for accelerating and maintaining pulmonary rehabilitation gains

NIH

open
OpenLast verified: 2026-06-20

About This Grant

Chronic Obstructive Pulmonary Disease (COPD) is a debilitating condition with a higher prevalence among Veterans compared to the general population. Pulmonary rehabilitation (PR) represents the most effective non- pharmaceutical treatment option for control of daily symptoms and promoting functional independence. Successful completion of PR is roundly thought to improve quality of life. While the benefits of PR are well documented, there is a critical need to improve PR outcomes, accelerate response to PR, and maintain gains made in programs. In this randomized controlled trial, we will test the impact of a portable, user-friendly positive expiratory pressure device (PEP Buddy) as an additional tool used in PR vs. sham. This study investigates outcomes in both the active PR setting and post discharge. In preliminary studies, PEP Buddy has been shown to improve symptoms and quality-of-life scores, improve walk distance, and enhance physiological response to exercise after a brief time in persons with COPD and excessive dynamic airways collapse. Based on promising preliminary data, we propose investigation of outcomes over the course of PR and post-discharge to define the utility of PEP Buddy as an integral tool for COPD patients. Further, we find it necessary to fully define the effect of PEP Buddy on respiratory mechanics during exercise and have developed an aim using modified graded cycle ergometry that will thoroughly define the differential exercise physiology when the PEP Buddy is being used vs not by employing a cross-over study. As stated above, the main benefits of PR fall into a multitude of domains including psychological, functional, and physiological which we will investigate separately in this trial. The trial will run for four years, in the first three years we will recruit at least 120 new enrollees to PR with COPD, block randomized into equally-sized, double-blinded cohorts of PEP Buddy vs. sham. Our center actively enrolled ~140 COPD participants in pulmonary rehabilitation in Fiscal Year 2021 among ~220 referrals, with increases in 2022 and 2023, respectively. Outcomes will be collected at enrollment, every three weeks up to discharge, and at the six- and 12-month time periods after enrollment (e.g., post-discharge outcomes). In AIM 1a, we will compare total and rate of improvements in validated psychological and quality-of-life questionnaires between groups at each time point. We hypothesize that those in the PEP Buddy arm will show greater improvements earlier in their PR course and maintain the gains made in PR after discharge. AIM 1b assesses the results of actigraphy monitoring, walk distance, sit-to-stand testing, and other metrics of functional status in PEP Buddy vs. sham. Similar to quality-of-life and psychological scores, we expect improvements to be seen early in the PR course and be greater over the course of PR and after discharge. Our rationale for these hypotheses is that PEP Buddy will provide a readily accessible tool to overcome the symptoms of dynamic hyperinflation, assist in breathing control, and allow PR participants to recover more quickly and thoroughly from exercise-induced symptoms when compared to those learning the standard techniques in PR. In AIM 2, we will select 30 participants from Aim 1a/b and perform a crossover study utilizing graded cycle ergometry and dynamic tidal volume measurements to define the differences in the physiologic response to exercise when using the PEP Buddy device and when not. This will define the mechanism by which PEP Buddy is effective in preventing dynamic hyperinflation and increasing work output in those with COPD. At the conclusion of this study, we will have identified a user-friendly device that can be readily implemented into any PR program that promotes self-efficacy, directly enhances the response to PR, and leads to maintained PR gains. As the availability of PR expands, we are hopeful that fully elucidating the benefits of tools such as PEP Buddy will directly benefit Veterans by promoting self-efficacy and independence, increasing confidence in controlling daily symptoms, and maximizing the response to the effort these men and women put into PR training.

Grant Summary

A randomized, sham controlled clinical trial to assess the effectiveness of a positive end expiratory device for accelerating and maintaining pulmonary rehabilitation gains is a NIH grant providing funding that varies by award for university, nonprofit, healthcare org. Applications are due 2029-12-31 (open). Check eligibility and apply with FindGrants.

Not quite the right fit?

Search 9,000+ open grants, or get matches ranked for your organization — free.

Focus Areas

health research

Eligibility

universitynonprofithealthcare org

How to Apply

Funding Range

Up to $0K

Deadline

2029-12-31

Complexity
Medium
  1. 1Confirm your organization is eligible for A randomized, sham controlled clinical trial to assess the effectiveness of a positive end expiratory device for accelerating and maintaining pulmonary rehabilitation gains from NIH, checking organization type, location, and any population or project requirements.
  2. 2Gather the required documents and information, including your organization details, project plan, and budget figures.
  3. 3Draft your application narrative and budget addressing the funder's priorities and review criteria. FindGrants can draft each section for you to review and edit.
  4. 4Review every section against the requirements checklist, then export a submission-ready application pack and submit it to NIH before the deadline.
This record is a past award, contract, or funder profile — useful for research, but not an open grant application. Check the original source for current opportunities from this funder.

Don't want to draft it yourself?

We'll draft the complete application against NIH's requirements, run a quality review, and email you a submission-ready PDF plus an editable Word doc within 5 business days. Most orders deliver in 24-48 hours. Flat $399, any grant size.

AI Requirement Analysis

Detailed requirements not yet analyzed

Have the NOFO? Paste it below for AI-powered requirement analysis.

0 characters (min 50)

A randomized, sham controlled clinical trial to assess the effectiveness of a positive end expiratory device for accelerating and maintaining pulmonary rehabilitation gains: Frequently Asked Questions

Who is eligible for the A randomized, sham controlled clinical trial to assess the effectiveness of a positive end expiratory device for accelerating and maintaining pulmonary rehabilitation gains?

A randomized, sham controlled clinical trial to assess the effectiveness of a positive end expiratory device for accelerating and maintaining pulmonary rehabilitation gains is offered by NIH and is generally open to university, nonprofit, healthcare org. It is open to organizations nationwide unless the funder specifies otherwise. Review the specific eligibility terms before applying, since funders set their own requirements around organization type, location, and the population or project being served.

How much funding does the A randomized, sham controlled clinical trial to assess the effectiveness of a positive end expiratory device for accelerating and maintaining pulmonary rehabilitation gains provide?

A randomized, sham controlled clinical trial to assess the effectiveness of a positive end expiratory device for accelerating and maintaining pulmonary rehabilitation gains provides an amount that varies by award per award from NIH. Actual award sizes depend on the scope of your project, available program funds, and the number of applicants, so build a budget that reflects realistic, allowable costs rather than the maximum figure.

When is the A randomized, sham controlled clinical trial to assess the effectiveness of a positive end expiratory device for accelerating and maintaining pulmonary rehabilitation gains deadline?

Applications for A randomized, sham controlled clinical trial to assess the effectiveness of a positive end expiratory device for accelerating and maintaining pulmonary rehabilitation gains are due 2029-12-31 (open). Because deadlines can change, verify the date with the funder, NIH, and give yourself enough time to prepare a complete, competitive application before the close date.

How do you apply for the A randomized, sham controlled clinical trial to assess the effectiveness of a positive end expiratory device for accelerating and maintaining pulmonary rehabilitation gains?

To apply for A randomized, sham controlled clinical trial to assess the effectiveness of a positive end expiratory device for accelerating and maintaining pulmonary rehabilitation gains, confirm your eligibility, gather the required documents, and prepare a narrative and budget that address the funder's priorities. FindGrants guides you step by step and can draft each section, then exports a submission-ready application pack for this grant from NIH.